Reumatología al día

Efectividad de los FAMEb/sd, incluido ixekizumab por línea de tratamiento y FAMEsc concomitantes en artritis psoriásica: datos de vida real de un estudio observacional prospectivo.

Adela Gallego-Flores, Philipp Sewerin, Nicola Gullick, Hagen Russ, Khai Jing Ng, Meadhbh O’Neill, Sebastián Moyano, Federica Giurdanella, Francesco Ciccia

Características basales y eficacia en pacientes con espondiloartritis axial radiográfica (EspAax-r) estratificada por nivel de PCR: un análisis del ensayo de fase III con ixekizumab.

Raj Sengupta, Pedro M. Machado, Philippe Goupille, Victoria Navarro-Compán, Xu Huji, Mohamed Sheesh, Khai Jing Ng, Marcus Ngantcha, Hagen Russ, Gabriel Doridot, Xenofon Baraliakos

Pacientes con artritis psoriásica de un estudio comparativo de fase 4 estratificados por afectación ungueal.

Alen Zabotti, Alexis Ogdie, Masato Okada, Rebecca Bolce, Jeffrey Lisse, Marcus Ngantcha, Mohamed Taher, Khai Jing Ng, Dennis McGonagle

Comparative Persistence and Effectiveness of Ixekizumab Versus Other b/tsDMARD Classes in Real-World PsA Treatment: 12-Month Results From the PRO-SPIRIT Study

Philipp Sewerin, Helena Marzo-Ortega, Carlo Selmi, Hagen Russ, Khai Jing Ng, Inmaculada de la Torre, Marcus Ngantcha, Dominika Kennedy, Adela Gallego-Flores, Laura C. Coates

Efficacy of Ixekizumab in Radiographic Axial Spondyloarthritis Patients With Normal and Elevated CRP: A Pooled Analysis of Phase 3 Clinical Trials

Raj Sengupta, Xenofon Baraliakos, Pedro Machado, Philippe Goupille, Mohamed Sheesh, Khai Jing Ng, Mizan Alam, Rebecca Bolce, Yan Yan, Yu Xue, Martin Rudwaleit, Victoria Navarro-Compán

What is the profile of axial spondyloarthritis patients treated with ixekizumab and its effectiveness in clinical practice? Results from the ESPADA study

Cristina Campos, Mª Concepción Fito-Manteca, Cristina Valero-Martínez, Sara Garcia-Carazo, Silvia Díaz-Cerezo, Sebastián Moyano, Amelia Cobo, Itxaso Aguirregabiria, Clara Pérez-Rambla, FJ Pérez-Sádaba, Victoria Navarro-Compán

Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial

Raj Sengupta (Presenter), Pedro M. Machado, Philippe Goupille, Victoria Navarro-Compán, Xu Huji, Mohamed Sheesh, Khai Jing Ng, Marcus Ngantcha, Hagen Russ, Gabriel Doridot, Xenofon Baraliakos

Drug Persistence of IL-17A Inhibitors Among Patients With PsA: Real-World Data From the CorEvitas PsA/SpA Registry

Philip J. Mease, Nicole Middaugh, Maya Marchese, Skyler Peterson, Burcu Vardar, Russel Burge, Natalia Bello, Marcus Ngantcha, Joseph Merola, Louis Bessette, Alexis Ogdie

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

Kurt Oelke, Sarah Ross, Emily Edson-Heredia, Jennifer Marie Pustizzi, Ali Sheikhi Mehrabadi, Natalia Bello, Frederick Murphy, Shikha Singla, Siba Raychaudhuri, Phillip J Mease, Arthur Kavanaugh

Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

Kurt Oelke, Sarah Ross, Emily Edson-Heredia, Jennifer Marie Pustizzi, Ali Sheikhi Mehrabadi, Natalia Bello, Frederick Murphy, Shikha Singla, Siba Raychaudhuri, Phillip J Mease, Arthur Kavanaugh

Real-World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data From the European and Non-European Cohorts of the RA-BE-REAL Study

Rieke Alten , Gerd R. Burmester, Marco Matucci-Cerinic, Jens Gerwien, Walid Fakhouri, Samuel Ogwu, Ewa Haladyj, Inmaculada De La Torre, Bruno Fautrel, AJ Fernandez (Non-author Presenter)